AbbVie

Humira biosimilars arrive in the US, as Amgen launches first copycat to AbbVie’s blockbuster drug
BioPharma Dive
Tue, 01/31/23 - 12:37 pm
AbbVie
Humira
biosimilars
Amgen
The end of the Humira era
EP Vantage
Mon, 01/30/23 - 10:46 am
AbbVie
Humira
patents
biosimilars
Merck
Keytruda
Top 10 Pharma TV Ad Spenders in 2022 — Anti-Inflammatories and Diabetes Drugs Dominate
Xtalks
Sun, 01/29/23 - 01:31 pm
television ads
pharma marketing
DTC ads
AbbVie
Rinvoq
Dupixent
Sanofi
Regeneron
Skyrizi
Novo Nordisk
Ozempic
Jardiance
Eli Lilly
Boehringer Ingelheim
Rybelsus
Trulicity
Rexulti
Otsuka
Lundbeck
Tremfya
JNJ
Verzenio
AbbVie Is Set to Lose on Its Biggest Blockbuster. Here's Why You Shouldn't Worry.
Motley Fool
Sun, 01/22/23 - 01:01 pm
AbbVie
Humira
biosimilars
AbbVie, Novartis and more win national coverage in China even as Pfizer's Paxlovid gets left out
Fierce Pharma
Wed, 01/18/23 - 10:53 pm
AbbVie
Novartis
China
drug pricing
Pfizer
Paxlovid
Could This FDA Approval Boost AbbVie's Stock?
Motley Fool
Wed, 01/18/23 - 09:49 am
AbbVie
Vraylar
major depressive disorcer
Biopharma's stock market winners of 2022 revealed
EP Vantage
Wed, 01/18/23 - 09:46 am
pharma stocks
Merck
Eli Lilly
AbbVie
Daiichi Sankyo
Vertex Pharmaceuticals
Takeda
Sarepta Therapeutics
Halozyme
Horizon Therapeutics
AbbVie and Lilly have sent a warning signal to the UK government by leaving the voluntary medicines pricing agreement in protest over increasingly punitive revenue clawbacks
ABPI
Tue, 01/17/23 - 10:38 am
AbbVie
Eli Lilly
UK
NHS
drug pricing
Looking past Humira, AbbVie boosts sales forecasts for successor drugs
BioPharma Dive
Wed, 01/11/23 - 12:22 pm
JPMHC 2023
AbbVie
Richard Gonzalez
Pharma CEOs
Humira
Skyrizi
Rinvoq
AbbVie, following in footsteps of Lilly and Takeda, pays Anima $42M to go after undruggable targets
Fierce Biotech
Tue, 01/10/23 - 11:05 am
AbbVie
Anima Biotech
MRNA
small molecule drugs
oncology
immunology
undruggable targets
AbbVie inks Immunome solid tumor deal that could top $2.8B in biobucks
Fierce Biotech
Sun, 01/8/23 - 10:07 pm
AbbVie
Immunome
biobucks
solid tumors
The biggest-selling pharma companies of 2023
EP Vantage
Wed, 01/4/23 - 05:20 pm
Pfizer
Merck
JNJ
Novartis
AbbVie
Roche
AbbVie's Vraylar, carrying $4B sales target, wins FDA label expansion in depression
Fierce Pharma
Mon, 12/19/22 - 10:05 pm
AbbVie
Vraylar
depression
FDA
AbbVie leaves PhRMA, BIO: reports
Medical Marketing and Media
Thu, 12/15/22 - 11:20 pm
AbbVie
BIO
PhRMA
lobbying
AbbVie, Ipsen exit R&D deals to cap off lousy year for Exicure
Fierce Biotech
Wed, 12/14/22 - 10:44 am
Exicure
AbbVie
Ipsen
R&D
AbbVie slapped with age discrimination lawsuit, following other pharmas
Endpoints
Mon, 12/12/22 - 10:31 am
AbbVie
age discrimination
legal
ASH: Roche touts Lunsumio's durable efficacy as AbbVie, Regeneron plot lymphoma bispecific battle
Fierce Pharma
Mon, 12/12/22 - 10:21 am
Roche
ASH 2022
AbbVie
Regeneron
lymphoma
Lunsumio
glofitamab
AbbVie Launches Strategic Collaboration with HotSpot Therapeutics to Further Expand Immunology Pipeline
BioSpace
Tue, 12/6/22 - 10:42 am
AbbVie
HotSpot Therapeutics
drug discovery
drug development
autoimmune disease
BMS' Zeposia and AbbVie's Skyrizi Shake Up First-Line Prescribing Patterns in the US Ulcerative Colitis and Crohn's Disease Markets, Spherix Reports
PR Newswire
Sun, 12/4/22 - 01:24 pm
Bristol Myers Squibb
AbbVie
Zeposia
Skyrizi
ulcerative colitis
Crohn's Disease
gastroentrologists
10 Massachusetts Biopharma Companies Hiring Now
BioSpace
Fri, 12/2/22 - 11:18 am
Massachusetts
hirings
AbbVie
Moderna Therapeutics
CSL
Intellia Therapeutics
Schrödinger
Visterra
Alloy Therapeutics
Werewolf Therapeutics
Sherlock Biosciences

Pages